Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesús G. Berdeja, Sundar Jagannath, Arnob Banerjee et al.|The Lancet|2021Cited by 1.7k
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.Jesús G. Berdeja, Sundar Jagannath, Deepu Madduri et al.|Journal of Clinical Oncology|2020Cited by 78
Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.Sundar Jagannath, Jesús G. Berdeja, Deepu Madduri et al.|Journal of Clinical Oncology|2021Cited by 37
UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)Jesús G. Berdeja, Sundar Jagannath, Deepu Madduri et al.|Hematology Transfusion and Cell Therapy|2020Cited by 7
Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple MyelomaThomas Martin, Sundar Jagannath, Yi Lin et al.|Transplantation and Cellular Therapy|2021Cited by 3